Form 8-K - Current report:
SEC Accession No. 0001867096-25-000104
Filing Date
2025-06-04
Accepted
2025-06-04 17:17:41
Documents
13
Period of Report
2025-06-04
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K xers-20250604.htm   iXBRL 8-K 38059
  Complete submission text file 0001867096-25-000104.txt   188074

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xers-20250604.xsd EX-101.SCH 2036
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT xers-20250604_def.xml EX-101.DEF 15406
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xers-20250604_lab.xml EX-101.LAB 27075
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xers-20250604_pre.xml EX-101.PRE 16120
15 EXTRACTED XBRL INSTANCE DOCUMENT xers-20250604_htm.xml XML 2833
Mailing Address 1375 WEST FULTON STREET, SUITE 1300 CHICAGO IL 60607
Business Address 1375 WEST FULTON STREET, SUITE 1300 CHICAGO IL 60607 844-445-5704
Xeris Biopharma Holdings, Inc. (Filer) CIK: 0001867096 (see all company filings)

EIN.: 871082097 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40880 | Film No.: 251024097
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)